Dianthus Advances Claseprubart With Positive Phase 3 Update

Dianthus Therapeutics ( (DNTH) ) has shared an update.

On March 9, 2026, Dianthus Therapeutics reported fourth-quarter and full-year 2025 results and highlighted an early GO decision in its Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, after meeting responder criteria with fewer than 40 planned participants in Part A. The company also outlined progress across its portfolio, including plans to start a Phase 3 registrational trial of claseprubart in generalized myasthenia gravis in mid-2026, ongoing Phase 2 work in multifocal motor neuropathy, and a Phase 1 program for DNTH212, supported by a $514.4 million cash position as of December 31, 2025 that extends its runway into 2028 despite a wider annual net loss driven by higher R&D and G&A spending.

The early CAPTIVATE decision strengthens Dianthus’s bid to build a leading neuromuscular franchise around claseprubart, which is designed for infrequent, self-administered subcutaneous dosing and aims to shift the standard of care in high unmet-need autoimmune diseases. For stakeholders, the combination of accelerated clinical momentum, expanding trials in gMG and MMN, and substantial liquidity underscores both the company’s growing investment in late-stage development and its capacity to advance multiple autoimmune programs in parallel, albeit with increased operating losses reflecting its intensified clinical activity in 2025.

The most recent analyst rating on (DNTH) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Spark’s Take on DNTH Stock

According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.

The score is primarily held back by weak financial performance (declining revenue, ongoing losses, and negative operating cash flow) and a loss-driven negative P/E. It is supported by a constructive price trend above key moving averages and positive corporate developments (Phase 2 success and a new licensing collaboration).

To see Spark’s full report on DNTH stock, click here.

More about Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases, with a particular emphasis on neuromuscular disorders such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Its pipeline is led by claseprubart, a subcutaneous monoclonal antibody targeting the classical complement pathway, and DNTH212, a bifunctional fusion protein aimed at modulating both innate and adaptive immunity across multiple autoimmune indications.

Average Trading Volume: 794,851

Technical Sentiment Signal: Buy

Current Market Cap: $2.82B

Learn more about DNTH stock on TipRanks’ Stock Analysis page.